FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753187910> ?p ?o ?g. }

• W2753187910 endingPage "1469" @default.
• W2753187910 startingPage "1463" @default.
• W2753187910 abstract "Abstract Background Second-line therapy has consistently demonstrated survival benefit if compared with best supportive care; however, there is limited evidence whether further lines of treatment may improve the prognosis of advanced gastric cancer (AGC) patients. Materials and Methods Starting from a real-world cohort of 868 AGC patients, we retrospectively analyzed baseline parameters, tumor characteristics, and treatment data of those treated with at least three lines. Categorical features were described through cross-tables and chi-square test. We explored the impact of treatment intensity and progression-free survival (PFS) experienced in previous lines on PFS and overall survival in third-line by uni- and multivariate Cox regression models and described by Kaplan-Meier estimator plot with log-rank test. Results Overall, 300 patients were included in the analysis. The most common site of primary tumor was gastric body; 45.3% of cancers had an intestinal histotype, 14% were human epidermal growth receptor 2 positive. In third-line, 45.7% of patients received a single-agent chemotherapy, 49.7% a combination regimen. Patients who had experienced a first-line PFS ≥6.9 months had a better prognosis compared with those who had achieved a shorter one. Consistently, a second-line PFS ≥3.5 months positively influenced the prognosis. Patients receiving a third-line combination regimen had better outcomes compared with those treated with a single-agent chemotherapy. Conclusion Our real-world study confirms that selected AGC patients may receive third-line treatment. Longer PFS in previous lines or a more intense third-line treatment positively influenced prognosis. Further efforts are warranted to define the best therapeutic sequences, and to identify the optimal candidate for treatment beyond second-line." @default.
• W2753187910 created "2017-09-15" @default.
• W2753187910 creator A5002745641 @default.
• W2753187910 creator A5008135397 @default.
• W2753187910 creator A5013554030 @default.
• W2753187910 creator A5014792832 @default.
• W2753187910 creator A5015406288 @default.
• W2753187910 creator A5021631368 @default.
• W2753187910 creator A5022734154 @default.
• W2753187910 creator A5034035272 @default.
• W2753187910 creator A5034659601 @default.
• W2753187910 creator A5042064313 @default.
• W2753187910 creator A5043233794 @default.
• W2753187910 creator A5043785164 @default.
• W2753187910 creator A5049680516 @default.
• W2753187910 creator A5050575377 @default.
• W2753187910 creator A5051321693 @default.
• W2753187910 creator A5054443227 @default.
• W2753187910 creator A5054617465 @default.
• W2753187910 creator A5056137515 @default.
• W2753187910 creator A5065803904 @default.
• W2753187910 creator A5076272065 @default.
• W2753187910 creator A5076960990 @default.
• W2753187910 creator A5077674399 @default.
• W2753187910 creator A5079437223 @default.
• W2753187910 creator A5086984759 @default.
• W2753187910 creator A5088304855 @default.
• W2753187910 creator A5089737234 @default.
• W2753187910 creator A5090671983 @default.
• W2753187910 creator A5091765229 @default.
• W2753187910 date "2017-12-01" @default.
• W2753187910 modified "2023-10-11" @default.
• W2753187910 title "Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy" @default.
• W2753187910 cites W1968659207 @default.
• W2753187910 cites W2031489542 @default.
• W2753187910 cites W2032254515 @default.
• W2753187910 cites W2038274064 @default.
• W2753187910 cites W2055585836 @default.
• W2753187910 cites W2104631255 @default.
• W2753187910 cites W2104759721 @default.
• W2753187910 cites W2111237964 @default.
• W2753187910 cites W2114734455 @default.
• W2753187910 cites W2129801498 @default.
• W2753187910 cites W2132871418 @default.
• W2753187910 cites W2145390243 @default.
• W2753187910 cites W2148287035 @default.
• W2753187910 cites W2160161167 @default.
• W2753187910 cites W2235523093 @default.
• W2753187910 cites W2276228008 @default.
• W2753187910 cites W2335053383 @default.
• W2753187910 cites W2412860306 @default.
• W2753187910 cites W2472847770 @default.
• W2753187910 cites W2483618321 @default.
• W2753187910 cites W2508953175 @default.
• W2753187910 cites W2528338059 @default.
• W2753187910 cites W2564425059 @default.
• W2753187910 cites W2602826792 @default.
• W2753187910 cites W2612532430 @default.
• W2753187910 cites W2725487442 @default.
• W2753187910 cites W2736728025 @default.
• W2753187910 cites W2749878693 @default.
• W2753187910 doi "https://doi.org/10.1634/theoncologist.2017-0158" @default.
• W2753187910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813760" @default.
• W2753187910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29449512" @default.
• W2753187910 hasPublicationYear "2017" @default.
• W2753187910 type Work @default.
• W2753187910 sameAs 2753187910 @default.
• W2753187910 citedByCount "24" @default.
• W2753187910 countsByYear W27531879102018 @default.
• W2753187910 countsByYear W27531879102019 @default.
• W2753187910 countsByYear W27531879102020 @default.
• W2753187910 countsByYear W27531879102021 @default.
• W2753187910 countsByYear W27531879102022 @default.
• W2753187910 countsByYear W27531879102023 @default.
• W2753187910 crossrefType "journal-article" @default.
• W2753187910 hasAuthorship W2753187910A5002745641 @default.
• W2753187910 hasAuthorship W2753187910A5008135397 @default.
• W2753187910 hasAuthorship W2753187910A5013554030 @default.
• W2753187910 hasAuthorship W2753187910A5014792832 @default.
• W2753187910 hasAuthorship W2753187910A5015406288 @default.
• W2753187910 hasAuthorship W2753187910A5021631368 @default.
• W2753187910 hasAuthorship W2753187910A5022734154 @default.
• W2753187910 hasAuthorship W2753187910A5034035272 @default.
• W2753187910 hasAuthorship W2753187910A5034659601 @default.
• W2753187910 hasAuthorship W2753187910A5042064313 @default.
• W2753187910 hasAuthorship W2753187910A5043233794 @default.
• W2753187910 hasAuthorship W2753187910A5043785164 @default.
• W2753187910 hasAuthorship W2753187910A5049680516 @default.
• W2753187910 hasAuthorship W2753187910A5050575377 @default.
• W2753187910 hasAuthorship W2753187910A5051321693 @default.
• W2753187910 hasAuthorship W2753187910A5054443227 @default.
• W2753187910 hasAuthorship W2753187910A5054617465 @default.
• W2753187910 hasAuthorship W2753187910A5056137515 @default.
• W2753187910 hasAuthorship W2753187910A5065803904 @default.
• W2753187910 hasAuthorship W2753187910A5076272065 @default.
• W2753187910 hasAuthorship W2753187910A5076960990 @default.
• W2753187910 hasAuthorship W2753187910A5077674399 @default.
• W2753187910 hasAuthorship W2753187910A5079437223 @default.

• next